<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873091</url>
  </required_header>
  <id_info>
    <org_study_id>NJFY2016002</org_study_id>
    <nct_id>NCT02873091</nct_id>
  </id_info>
  <brief_title>Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia</brief_title>
  <official_title>Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Maternity and Child Health Care Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Maternity and Child Health Care Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixteen million babies were born in 2010, approximately half were by cesarean. Labor
      analgesia should be the first choice for these parturients based on the consideration of
      security and humanization. However this labor analgesia rate is quite low in China (&lt;5%)
      while in western country, this rate is up to 60%. Programmed intermittent epidural bolus
      (PIEB) is the latest technique for labor analgesia which has less neurotoxicity theoretically
      compared with Continuous Epidural Infusion(CEI) with Patient controlled epidural analgesia
      (PCEA) which is used most commonly. In that study, they reported less total local anesthetic
      consumption, fewer manual bolus doses and greater patient satisfaction with the PIEB
      technique. In China, multiple factors contribute to the reasons of low labor analgesia rate.
      From the patient's point of view, worrying about unsatisfied analgesia, and not adapted to
      the symptoms of motor block, such as inability to move their legs distressing, both are
      important reasons of refusing labor analgesia and preferring to cesarean delivery. Therefore,
      in this clinical trial, we plan to find a safer and more effective regimen for labor
      analgesia in Chineseparturients. This clinical trial is designed to prove PIEB used
      Ropivacaine is safer and more effective than CEI for labor analgesia in Chinese parturients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal visual analogue scale (VAS)</measure>
    <time_frame>At time of initiation of analgesia and hourly thereafter until 1 hours postpartum (approximately 10 hours)</time_frame>
    <description>a visual analog scale (VAS) with a 10 cm vertical score ranged from &quot;no pain&quot; to &quot;worst possible pain&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal modified Bromage scale</measure>
    <time_frame>At time of initiation of analgesia and hourly thereafter until 2 hours postpartum (approximately 10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Satisfaction with labor epidural analgesia</measure>
    <time_frame>At the time after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ropivacaine and sufentanil consumption</measure>
    <time_frame>At two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of parturients requiring additional PCEA boluses</measure>
    <time_frame>At two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of &quot;very satisfied&quot;and/or &quot;satisfied&quot;,Proportion of subjects who has experienced Visual analog scale (VAS) score for pain more than 3 scale</measure>
    <time_frame>At two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal heart rate</measure>
    <time_frame>At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of cesarean delivery and instrument-assisted delivery</measure>
    <time_frame>At time of placental delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>Initiation of analgesia to 2 h postpartum (approximately 10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durations of labor stages</measure>
    <time_frame>From the beginning of regular contraction of uterus to the end of the labor (approximately 12 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of oxytocin after analgesia</measure>
    <time_frame>At twenty-four hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal side effects</measure>
    <time_frame>Initiation of analgesia to 2 hour postpartum (approximately 10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar scale</measure>
    <time_frame>At the first and fifth minutes after baby was born</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal heart rate</measure>
    <time_frame>From initiation of analgesia to delivery (approximately 8 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal weight</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of PCEA</measure>
    <time_frame>At two hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal respiratory rate</measure>
    <time_frame>At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood pressure</measure>
    <time_frame>At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Labor Analgesia</condition>
  <arm_group>
    <arm_group_label>CEI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIEB 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIEB 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epidural analgesia</intervention_name>
    <arm_group_label>CEI</arm_group_label>
    <arm_group_label>PIEB 1</arm_group_label>
    <arm_group_label>PIEB 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous epidural infusion</intervention_name>
    <arm_group_label>CEI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intermittent epidural bolus</intervention_name>
    <arm_group_label>PIEB 1</arm_group_label>
    <arm_group_label>PIEB 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <arm_group_label>CEI</arm_group_label>
    <arm_group_label>PIEB 1</arm_group_label>
    <arm_group_label>PIEB 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <arm_group_label>CEI</arm_group_label>
    <arm_group_label>PIEB 1</arm_group_label>
    <arm_group_label>PIEB 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who agree to join this study

          -  Age: 22y-40y

          -  American Society of Anesthesiologists (ASA) physical status 1 or 2

          -  Gestation : 37-41 weeks

          -  Primipara

          -  Singleton fetus and head presentation

          -  In early labor: cervical dilation for 1-3cm

          -  Requesting labor epidural analgesia

        Exclusion Criteria:

          -  Contraindication for epidural analgesia

          -  Height less than 150 cm or more than 170 cm

          -  Morbid obesity (BMI more than 35)

          -  High-risk pregnancy:(gestational diabetes mellitus, gestational hypertension, placenta
             previa, placental abruption, preeclampsia)

          -  Received parenteral opioids

          -  Unable to perform motor block evaluation tests
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caijuan Li, M.A.</last_name>
    <phone>025-52226112</phone>
    <email>licaijuanyumi1228@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanwu Feng, MD</last_name>
      <email>shanwufeng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>December 27, 2016</last_update_submitted>
  <last_update_submitted_qc>December 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Maternity and Child Health Care Hospital</investigator_affiliation>
    <investigator_full_name>Caijuan Li</investigator_full_name>
    <investigator_title>Nanjing Maternity and Child Health Care Hospital</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

